|Journal||Journal of Allergy and Clinical Immunology: In Practice|
|Early online date||2021|
|Publication status||Published - Sep 2021|
Access to Document
Other files and links
Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis. / Lugogo, Njira; Liu, Mark C.; Pavord, Ian; Mitchell, Patrick D.; Smith, Steven G.; Mallett, Stephen; Albers, Frank C.; Bradford, Eric S.; Yancey, Steven W.; Bel, Elisabeth H.In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, No. 9, 09.2021, p. 3506-3509.e3.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis
AU - Lugogo, Njira
AU - Liu, Mark C.
AU - Pavord, Ian
AU - Mitchell, Patrick D.
AU - Smith, Steven G.
AU - Mallett, Stephen
AU - Albers, Frank C.
AU - Bradford, Eric S.
AU - Yancey, Steven W.
AU - Bel, Elisabeth H.
N1 - Funding Information: Conflicts of interest: N. Lugogo reports grant support and advisory board fees from GSK; grant support, consulting fees, and advisory board fees from AstraZeneca; consulting fees, advisory board fees, and grant support from Teva Pharmaceuticals; grant support and advisory board fees from Genentech; grant support and advisory board fees from Sanofi/Regeneron; and advisory board fees from Novartis. M. C. Liu reports grants from Boehringer Ingelheim, Gossamer Bio, GSK, MedImmune, and Mereo BioPharma. I. Pavord reports that he has received speaker's honoraria for sponsored meetings from AstraZeneca, Boehringer Ingelheim, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, and GSK; and payments for organizing educational events from AstraZeneca, GSK, Sanofi/Regeneron, and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi, and Knopp; and payments to support US Food and Drug Administration approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, AstraZeneca, Teva, and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer, and Insmed. In 2014 to 2015, he was an expert witness for a patent dispute involving AstraZeneca and Teva. P. D. Mitchell reports that he has received speaker's honoraria for sponsored meetings from AstraZeneca, Boehringer Ingelheim, Novartis, Teva, Sanofi/Regeneron, and GSK; and payments for organizing educational events from AstraZeneca, GSK, Sanofi/Regeneron, and Teva. He has also received honoraria for attending advisory panels with GSK, AstraZeneca, and Sanofi/Regeneron. S. G. Smith, S. Mallett, and S. W. Yancey are employees of GSK and hold stock/share options in GSK. F. C. Albers was an employee of GSK at the time of the analysis and holds stocks/share options in GSK; he is now employed by Avillion. E. S. Bradford was an employee of GSK at the time of the analysis and is currently employed by Aeglea BioTherapeutics and owns stocks/shares in GSK and Aeglea BioTherapeutics. E. H. Bel reports grants from AstraZeneca, GSK, Novartis, and Teva; and personal fees from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Sanofi/Regeneron, Teva, Sterna Biologicals, Vectura, and Chiesi. Funding Information: Editorial support (in the form of writing assistance, including preparation of the draft manuscript under the direction and guidance of the authors, collating and incorporating authors' comments for each draft, assembling tables and figures, grammatical editing and referencing) was provided by Roisin McCorkell, MSc, at Fishawack Indicia Ltd, United Kingdom, part of Fishawack Health, and was funded by GlaxoSmithKline. S. G. Smith, S. Mallett, F. C. Albers, E. S. Bradford, and S. W. Yancey were involved in the conception or design of the analyses; N. Lugogo, M. C. Liu, and I. Pavord were involved in the acquisition of data; and all authors were involved in analyzing or interpreting the data and drafting the work or revising it critically for important intellectual content. All authors gave final approval of the version to be published, and agreed to be accountable for all aspects of the work. Anonymized individual participant data from the studies listed within this publication and the associated documents can be requested for further research from www.clinicalstudydatarequest.com . Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/9
Y1 - 2021/9
UR - http://www.scopus.com/inward/record.url?scp=85108793157&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jaip.2021.05.024
DO - https://doi.org/10.1016/j.jaip.2021.05.024
M3 - Article
C2 - 34111572
VL - 9
SP - 3506-3509.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2201
IS - 9